HealthDay News — Atogepant appears to be effective and well tolerated for the preventive treatment of migraine, according to a study published online June 8 in JAMA Network Open.

Richard B. Lipton, MD, from Albert Einstein College of Medicine and the Montefiore Headache Center in New York City, and colleagues evaluated the efficacy and safety of atogepant for the preventive treatment of migraine from December 14, 2018, to June 19, 2020, in adults seen at 128 US sites with 4 to 14 migraine-days per month. Analysis included patients randomly assigned to 10mg of atogepant (214 patients), 30mg of atogepant (223 patients), 60mg of atogepant (222 patients), or placebo (214 patients) once daily in 12 weeks.

The researchers found that a 50% or greater reduction in the mean of mean monthly migraine-day (MMD) was achieved by 55.6% treated with 10mg of atogepant (odds ratio, 3.1), 58.7% treated with 30mg atogepant (odds ratio, 3.5), 60.8% treated with 60mg of atogepant (odds ratio, 3.8), and 29% receiving placebo. A 25% or greater reduction in the 12-week mean of MMDs was achieved by 73.4, 77.1, 81.1, and 58.9%, respectively, while a 75% or greater reduction in mean MMDs was achieved by 30.4, 29.6, 37.8, and 10.7%, respectively. A 100% reduction in mean MMDs was achieved for 7.9% with 10mg, 4.9% for 30mg, and 7.7% for 60mg of atogepant vs 0.9% with placebo.

“At all doses, atogepant was effective during the 12-week double-blind treatment period beginning in the first 4 weeks, as evidenced by significant reductions in mean MMDs at every responder threshold level,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Allergan, which manufactures atogepant and funded the study.

Abstract/Full Text